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Abstract Therecommendedmethod tomeasure exhalednitricoxide (NO) cannotreveal the source of NOproduc-
tion.We applied a model based on the classical Fick’s ¢rst law of di¡usion to partition NO in the lungs.The aimwas to
develop a simple and robust solution algorithmwith a data quality control feature, and apply it to patients with known
alterationsin exhaledNO.Subjectswith allergic rhinitis, allergic asthma, chronicobstructivepulmonarydisease (COPD)
smokers and controls were investigated.NO was measured at three expiratory £ow rates. An iteration method was
developed to partition NO.The airway tissue content of NOwas increased in asthma,144780 ppb (P= 0?04) and de-
creased in smokers, 56736 ppb (P= 0?02).There was no di¡erence between subjects with rhinitis, 98740 ppb and
controls, 98744 ppb. The airway transfer rate was increased in allergic asthma and allergic rhinithis, 1274 vs.
1275mlsecÿ1, compared to controls, 872mlsecÿ1 (Po0?001). The alveolar levels were no di¡erent from controls,
271ppb. In COPD the alveolar levels were increased,472 ppb (Po0?001).Extended NO analysis reveals fromwhere
inthe respiratory systemNOisgenerated.Hence, this new testcan be added to the tools the physicianhas for the diag-
nosis and treatmentof patientswithrespiratorydisorders.r2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1204, available online athttp://www.idealibrary.comon
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The detection of nitric oxide (NO) in the exhaled gas (1)
has opened up a new research ¢eld. Many investigations
have been performed in patients su¡ering fromupper or
lower airways diseases. Increased levels have been found
in patients with asthma (2), allergic rhinitis (3) and
chronic obstructivepulmonarydisease (COPD) (4).Con-
fusingly, normal levels have been reported in non-atopic
asthma (5) and decreased levels have also been reported
in COPD (6). NO in exhaled gas appears to be a more
complex and intriguingmolecule than ¢rst expected.
An attempt to distinguish between theNOgenerated
in the alveolar region and in the airways was made by
Tsoukias and George (7). A plot of the exhaled volume
of NO versus the expiratory £ow rate was used, where
the slope of the curverepresents the alveolar concentra-
tion and the intercept the airway NO-£ux. Using this
model we have found that the increase in exhaled NOReceived1June 2001, accepted16 August 2001and published online14
November 2001.
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airways and that the alveolar region had normal NO
levels (8).This seems to be logic since asthma is an airway
disease.
The NO output has be shown to be £ow-dependent
(9,10). The mechanism behind the £ow dependency of
the NO output from the lower airways has been
suggested to be di¡usion-related (7). Applying a simpli-
¢edmodel andmathematics based on the classical Fick’s
¢rst law of di¡usion (11) on the concept of Tsoukias and
George, we derived an equation (12) for theNO concen-
tration as a function of exhaled £ow.Themodelhas three
unknown variables FANO (fraction of alveolar NO),
FwNO (fraction of NO in the airway wall tissue) and
DwNO (rate of NO transferred from the airway wall). If
enough data points for NO concentration at various
£ows are measured, it is possible to ¢nd their value by a
recursive least square ¢tting (LSF) algorithm (12^14).For
three unknown variables at least three data points are
required, but it turned out that the LSF may not be an
optimal tool to give reliable results when applied
to this type of a function if only a few data points are
available (12).
Our aim was to (a) develop a simple and robust solu-
tion algorithm with a data quality control feature as an
ITERATIONNOANALYSIS 25alternative for the LSF and (b) apply it to patients with
known alterations in exhaled NO in an attempt to
get more knowledge of the site of NO production. A
pilot study was therefore performed in patients
with COPD, asthma, allergic rhinitis and healthy
subjects that were divided into smokers and non-
smokers.
METHODS
The procedure to calculate the components
of exhaledNOoutput
The model consists of an alveolar compartment, and a
conductive airway compartment modelled as a cylindri-
cal tubewith a di¡usion barrier layer between the tissue
and airway.Based on thismodelwe derived the following
equation for the exhaledNO concentration as a function
of £ow rate ( _Q) (12):
FENO  FwNOÿ FwNOÿ FANO  eÿ
DwNO
_Q : 1
Wenextutilize theNO output _VENO as suggestedby
(7), and get:
_VENO  _Q
 FwNOÿ FwNOÿ FANO  eÿ
DwNO
_Q
 
: 2
At high £ows, when _Q DwNO, the linear approxi-
mation of the exponential function is 1ÿDwNO= _Q and
aftermanipulationwe get:
_VENO  FENO  _Q
 FwNOÿ FANO DwNO FANO  _Q: 3
This is an equation of a linewith a slope:
S  FANO: 4
Its intercept (I) with the vertical _VENO-axis can be
found, by setting _Q  0, to be:
I  FwNOÿ FANO DwNO: 5
We calculated the three unknown variables
FwNO, FANO and DwNO based on the measurement
of FENO at only three di¡erent £ows. The two
highest £ows are chosen to allow determining FANO
as a slope from eqn (4), and then ¢nding the intercept
eqn (5). The smallest £ow should be as low as
practically possible to then solve FwNO and DwNOreli-
ably. We have chosen to use the £ows 0?005, 0?1 and
0?5 l secÿ1 (12).
As an alternative for the sometimes problematic LSF
method we developed a spread sheet calculation algo-
rithm based on an iterative process using eqns (1), (4)
and (5). The method and its validation are described in
detail in Appendix1.Validation of the iterationNOanalysis
The eqn (1) based on the model shared byTsoukias and
George, Silko¡ et al., J˛rres, and H˛gman et al. (7,12^14)
is highly non-linear, and has a mathematical character
requiring special care in ¢tting of the measured data.
The slope of the function is strongly negative at low
£ows and then the validity of the data depends critically
on the accuracy of the £owmeasurement. At high £ows
the very small concentrations challenge the NO
measurement.
We compared three di¡erentmethods for calculating
the threevariables of themodel functionby analysing the
complete individual data in the 10 healthy subjects mea-
sured at 11 £ow rates. We applied non-weighted least-
square-¢tting (LSF) ¢rst on all the11 £ows and then only
on the three £ows (5,100 and 500ml secÿ1) for each indi-
vidual. Those were compared with our new iteration
method.
With the same data setwe also checked the feasibility
of themodelbehind the eqn (1).For each subjectwe ¢rst
calculated FwNO, FANO and DwNO using the data
measured at 0?005, 0?1and 0?5 l secÿ1and then using eqn
(1) predicted the NO concentrations for all the remain-
ing eight £ows (25, 50, 75, 150, 200, 250, 300 and
400ml secÿ1). These were compared to the measured
oneswith the Bland^Altman analysis (15).
Study subjects
The asthmatics (n=15) had symptomatic airway hyper-
reactivity and were clinically diagnosed by a chest physi-
cian.They werenon-smokers, atopic andhadrespiratory
symptoms during the last12 months.They were treated
with inhaled corticosteroids 200^800mg per day (age
38717 years, height17379 cm, weight 69719kg).
The subjects with allergic rhinitis (n=15) were clini-
cally diagnosed by a chest physician, but had no respira-
tory symptoms, andwere treatedwith anti-histamine on
demand (age 33714 years, height 17278 cm, weight
6978kg). The study was performed out of the pollen
season.
The smokers were recruited from hospital employees
and had reported no respiratory symptoms (age 4278
years, height17176 cm,weight 6579kg).They were cur-
rently smoking between 3^28 cigarettes per day (1076).
The COPD patients (n=20) were recruited from the
hospital COPD training courses (age 59712 years, height
17278 cm, weight 68712kg).They were all ex-smokers.
They were treated with inhaled corticosteroids
200^1600mg per day (n=18) and four of these were also
taking oral prednisolone. Two patients were not on any
treatment.
The control subjects (n=40) were healthy and had no
respiratory symptoms during the last month (age 3479
years, height17379 cm, weight 68713kg).
26 RESPIRATORYMEDICINEThe Human Ethics Committee at the Uppsala Univer-
sity approved the study. All subjects were fully informed
of the study and oral consentwas obtained.
NOmeasurements and analysing
equipment
Theguidelines forNOmeasurements (16)were followed,
except using three £ows (0?005, 0?1 and 0?5 l secÿ1) and
no vital capacity manoeuvre, since a deep breath with
slow inhalation was found su⁄cient (12). A mean value
of three breaths was used for the analysis.
The NO and end-tidal CO2 concentrations, £ow rate
and airway pressure were measured with a computer-
based single-breath NO system from Nitrograf AB,
HÌsselby, Sweden. The system includes a Sievers NOA
280 chemiluminescence analyser (Sievers, Boulder, CO,
U.S.A.) which was calibrated using a mixture of 509ppb
NO in nitrogen (AGA AB, Liding ,˛ Sweden) and the zero
was set by feeding synthetic air (AGA AB) into a 2 l
canister ¢lled with Pura¢l II chemisorbant (Lindair AB,
Ljusne, Sweden). The £ow sensor, D-liteTM (Datex-
Ohmeda, Helsinki, Finland) was calibrated in the range
of 0^0.6 l secÿ1 (Dry Cal DC-2 £ow calibrator, BIOS In-
ternational, Pompton Plains, NJ,U.S.A.).Controls of cali-
bration and £ow rate of the sampling systemwere done
daily and the zero was controlled before each measure-
ment.The ambient NO-levels were alwayso5ppb.FIG. 1. ABland^Altman plot to test the validity of the di¡usion m
subjects.For each subjectwe ¢rstcalculated FwNO,FANOand Dw
using eqn (1) predicted the NO concentrations for all the remaining
measured data of the eight remaining £ows.The lines for bias (0?17
suggests the data to be in good agreementwiththemodel andreveAnalysis of data
Data are presented as mean 7standard deviation (SD).
Bland^Altman analysis was used for the validation of
the NOmeasurements (15). Analysis of variance (ANO-
VA) and post hoc comparisons evaluated di¡erences
between patients group with Newman^Keuls test. For
all statistical calculations the Statistica/w 5.0 software
package (StatSoft Inc., Tulsa,OK,U.S.A.) was used. A P-
value ofo0?05 was considered statistically signi¢cant.
RESULTS
Validation of themodel andmethod
Applying the Bland^Altman analysis on the eight mea-
sured data points vs. the values predictedby the di¡usion
model in 10 subjects, gave a bias of 0?17ppb and a SD of
2?20ppb (Fig. 1). This suggests that the model described
by eqn (1) is consistentwith the experimental data. Inter-
estingly, the Bland^Altman plot also revealed three
outliers, all of them at the £ow of 0?025 l secÿ1.This was
actually the lowest measured £ow, because 0?005 l secÿ1
was generated by the sampling pump. Inaccuracies in
measuring the £ow or failure of the subject to maintain
the target £ow, may be the reason for these outliers
because of the high negative slope of themodel function
at low £ows. Removing the three outliers would reduce
thebias toÿ0?06ppb and standarddeviation to 0?92ppb.odel.The exhaled NO fraction was measured at 11 £ows on 10
NOusing the datameasured at 0?005,0?1and 0?5 l secÿ1and then
eight £ows.The plot was then generated using the predicted and
ppb) and bias72 SD (ÿ4?23 and +4?47 ppb) are shown.The plot
als three outliers.
ITERATIONNOANALYSIS 27The results of FANO, FwNO and DwNO for the 10
healthy subjects for all the three methods are shown in
Table1.With threeunknownvariables the LSF applied on
three £ows gives in principle anunique solution, butdoes
not provide any inherent control of the data quality.The
results of extendedNOanalysis are closely identicalwith
it and in addition the quality control feature is included.
The LSF with 11 £ows gives clearly erroneous values in
half of the cases (subjects1, 2, 4, 6 and 9).
Application of the iterationNOanalysis
The FENO0.1 was signi¢cantly higher for the asthmatics
than for the control group (P=0?003).The smokers had
a signi¢cant lower value than patients with COPD, aller-
gic rhinitis (P=0?020 respectively) and allergic asthmaTABLE 2. The calculationsof fractionof NOinthe airwaywall (F
and the alveolar fraction of NO (FANO) using iteration NO ana
medianvalues
Controls
(n= 40)
Allergic rhinitis
(n= 15)
FENO0?1 (ppb) 8?873?8
(8?0)
12?976?7
(11?7)
FANO (ppb) 1?970?9
(1?8)
1?870?6
(1?9)
DwNO (mlsec
ÿ1) 7?772?5
(7?3)
11?874?9*
(10?6)
FwNO (ppb) 97?6744?5
(96?7)
98?4739?6
(104?0)
ANOVA,Newman-Keuls test, *di¡erent from control, Po0?
Po0?05.
TABLE 1. Comparison of NO fraction in the airway wall (FwNO
the alveolar fractionof NO (FANO) obtainedwiththe extended
applied on three and11 £ows in healthy subjects.Note themajor
value of FwNOwhenusing the11 £owrates
Patient No. 1 2 3 4 5
Iteration NOanalysis
DwNO 4?69 9?20 6?62 9?52 12?65
FwNO 141?01 42?30 124?99 79?25 112?64 31
FANO 1?64 1?34 1?99 1?86 1?42
Least square ¢ttingwiththree £owrates
DwNO 4?76 9?37 6?73 9?70 12?93
FwNO 140?00 42?09 124?13 78?87 112?37 32
FANO 1?64 1?33 1?99 1?85 1?40
Least square ¢ttingwith11 £owrates
DwNO 10?87 5?03 6?26 5?09 15?45
FwNO 97?96 55?55 128?55 104?34 109?20 40
FANO ÿ0?48 1?62 2?00 2?96 0?02(Po0?001). (Table 2). Using three di¡erent expiratory
£ow rates and computing FANO (Po0?001), FwNO
(Po0?001) and DwNO (P=0?004) yielded di¡erences
between subjects with asthma, allergy, COPD and sub-
jects that smoked tobaccowith healthy control subjects.
The control subjects had a FwNO of 97?6744?5ppb, a
DwNO of 7?772?5ml sec
ÿ1 and FANO of 1?970?9ppb.
The validity index as de¢ned by the eqn 15 was in the
range of 8^17.
The asthmatics had an increased FwNO compared to
the control subjects (P=0?025). There was also an
increase in DwNO (Po0?001) while the FANO was no
di¡erent from the control subjects. (Table 2).Thevalidity
index was in the range of 6^13.
Interestingly, the DwNO in rhinitis was similar to the
asthmatics despite these subjects reported no airway
symptoms (Po0?001 compared to controls), while thewNO), thetransferrate of NOover the airwaywall (DwNO)
lysis.Data are given in mean7SD and in parenthesis are the
Allergic asthma
(n= 15)
Smokers
(n= 20)
COPD
(n= 20)
18?0712?5*
(14?7)
5?773?0
(5?2)
13?3713?0z
(9?1)
1?770?6
(1?8)
2?170?7
(1?9)
3?972?0*z
(3?0)
11?973?7*
(12?0)
7?874?0
(7?2)
10?578?3
(8?3)
143?8779?9*w
(145?3)
56?2736?0*
(49?5)
108?3766?3z
(103?6)
05, wdi¡erent from allergy, Po0?05, zdi¡erent from smokers,
), the transfer rate of NO over the airway wall (DwNO) and
NOanalysis calculated fromthree £owrates, and LSFmethod
di¡erences in the results of patients1, 2,4, 5,9 and themean
6 7 8 9 10 Mean SD
2?62 7?81 8?90 3?08 6?28 7?14 3?12
4?60 77?21 47?13 91?06 48?12 107?83 80?10
1?71 2?40 1?03 1?31 1?38 1?61 0?40
2?56 7?95 9?07 3?07 6?38 7?25 3?22
2?03 76?75 46?88 91?65 47?78 108?25 82?27
1?71 2?40 1?03 1?31 1?38 1?60 0?40
1?92 5?76 7?48 0?20 5?86 6?39 4?29
5?41 88?75 50?34 1043?34 49?76 213?32 309?62
1?74 2?69 1?45 1?71 1?56 1?53 1?05
TABLE 3. The di¡erences between patients with COPD when dividing them up after high (group A) or low (group B) NO
transfer rate (DwNO).The fraction of NO in the airway wall (FwNO) and the alveolar fraction of NO (FANO) are also pre-
sented.Data are given inmean7SD and inparenthesis are themedianvalues.Data for the controls can be seen inTable1
Group A
(n= 10)
Group B
(n= 10)
FENO0?1 (ppb) 18?6716?7* 8?074?2
w
(10?7) (7?4)
FANO (ppb) 4?672?5*
(4?1)
3?271?1*w
(2?9)
DwNO (mlsec
ÿ1) 16?877?3*
(14?6)
4?272?0 *w
(5?2)
FwNO (ppb) 86?9760?0
(55?9)
129?7768?2
(124?2)
ANOVA,Newman-Keuls test, *di¡erent fromcontrol, Po0?05. wdi¡erent fromgroup A, Po0?05.
28 RESPIRATORYMEDICINEFwNO was not di¡erent from the control. The FANO
was not di¡erent from the control subjects. (Table 2).
The validity index was in the range of 4^13.
Smoking subjects showed a decrease in FwNO com-
pared to the controls (P=0?042). There was no
di¡erence in DwNO and FANO compared to the
controls (Table 2).The validity index was in the range of
7^22.
FANO was signi¢cantly increased in patients with
COPD compared to all the other subjects (Po0?001)
(Table 2). There was a big range in DwNO
(0?8^34?1ml secÿ1).None of the COPD patients fell into
the 95% con¢dence intervals of thehealthy subjects, they
were either below or above. Therefore these subjects
were divided into two groups; one that had high (group
A) and one that had low (group B)DwNO.FromTable 3 it
can be seen that there was a clear di¡erence in the
DwNO (Po0?001). The high DwNO gives a signi¢cant
higher FENO0?1 than for patients with a low DwNO
(P=0?002).The patients with a low DwNO had a slightly
higher FwNO, which did not reach statistical signi¢cance
(P=0?054). There was also an increase in FANO in the
group A (Po0?001) and B (P=0?017). The validity index
was in the range of 3^23.
DISCUSSION
This pilot study that investigated the use of extended
NO analysis, in particular the iteration method, shows
that we have a new promising tool to partition exhaled
NO. In COPD we found both low and high airway trans-
fer rates of NO and high levels of NO from the alveolar
region. We found similarities between allergic asthma
and allergic rhinitis in an increased airway transfer rate
despite that therhinitis subjectsreportedno respiratory
symptoms.Wemade important ¢ndings regarding the robustness
of the extendedNOanalysis.Firstly, it is essential to base
the selection of the £ow rates and number of them on
thorough understanding of the character of the mathe-
matical formula describing the di¡usion-based model.
Secondly, the requirements for the accuracy of the £ow
and concentration measurements depend strongly on
the £ow. Our experience indicates that one very low
£ow, one medium £ow (around 0?1l secÿ1) and one high
£ow (preferably between 0?4^0?5 l secÿ1) are needed,
and use of additional £ows gives practically no more
information. At the very low £ow the use of a suctioning
pump with a constant £ow is a must to guarantee
adequate accuracy of the iteration method. In further
studies, a tool for on-line calculations will be needed.
Our mathematical tool running in any standard spread-
sheet program has this capability with an additional fea-
ture to test the consistencyof the datawith the di¡usion
model.
Using an extended NO analysis we can partition the
exhaled NO fractions into alveolar fractions, airwaywall
fraction and di¡usion rate. The alveolar fraction may
re£ect the ventilation^perfusion matching of the lung.
When there is a good ventilation^perfusion matching
the inhaled NO will contribute to an increase in oxygen
tension of the blood. If the ventilated areas are not well
perfused theNOmaynotbemetabolized andwill return
to the upper airways when exhaled.The higher FANO in
the patients with COPD might be interpreted as a poor
ventilation^perfusion matching, a known phenomena in
this group of patients. Another cause for an increased
FANO could simply be due to an up-regulation of induci-
blenitric oxide synthase in this region. A thirdcausecould
possibly be that there is a chemical interplay of NO and
human haemoglobin, i.e. S-nitrosylation, that hypotheti-
cally can release NO into the gas phase (17). Further stu-
dies have to address these di¡erent possibilities.
ITERATIONNOANALYSIS 29During exhalation the alveolar fraction of NO moves
up the airway tree and the exhaled gas will cumulate
NO due to di¡usion of NO from the airway wall. It is
not surprising to ¢nd an increase in FwNO in asthma
since it is an in£ammatorydisease of the airways.Thede-
crease in FwNO seen in our smokers ismost likely due to
a down-regulation of NOS activity since the airways
are exposed to high levels of NO from the cigarette
smoke (18).
Since NO di¡uses over to the exhaled gas, the airway
wall is not only a producer of NO, but also contains a
barrier for this di¡usion.TheDwNOrepresents the abil-
ity of the barrier to transfer NO. When there is an
epithelial damage, such as in asthma, one would expect
to have an increase in the DwNO. It is interesting that
subjects with rhinitis also have an increase in DwNO
despite no airway symptoms. This high transfer rate
might be the explanation for the increased exhaled NO
values reportedbyHenriksen et al. in patientswith aller-
gic rhinitis (3). A majority of allergic subjects have bron-
chial hyperreactivity and a high frequency of subjects
with allergic rhinitismaydevelop asthma.Further studies
have to investigate whether the DwNO can be used to
predict hyper-reactivity.
If there were a thickening of the airway walls both
by an increase in basement membrane, epithelial
layer and production of mucus, one would expect a de-
crease in DwNO. Applying extended NO analysis to
COPD patients we found that there was a clear-cut
di¡erence in the DwNO. This could explain the di¡-
erence in results in exhaled NO found in these patients
(4,6).
In conclusion, we have introduced an extended NO
analysis, giving the alveolar fraction, the transfer rate
and the airway wall fraction of NO, with a new robust
and simple iteration calculation method. We now have
to investigate the correlation of these calculated NO
values to in£ammatorymarkers, lung functionmeasure-
ments, and treatment with both old and new drugs that
may a¡ect these values.
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APPENDIX1
The iteration algorithm for calculation of
FwNO,FANOand DwNO
Let the NO concentrations measured as ppb’s from the
mouth by a standard procedure (16) at £ows 0?005, 0?1
and 0?5 l secÿ1, be FENO0?005, FENO0?1 and FENO0?5, re-
30 RESPIRATORYMEDICINEspectively.Then the slope and interceptcanbe calculated
by employing basic geometry:
S  FANO
 500  FENO05 ÿ 100  FENO01=500ÿ 100
 1  25FENO05 ÿ 0  25FENO01 A1
I  100  FENO01 ÿ 100  S
 125  FENO01 ÿ FENO05: A2
For solving FwNO and DwNO we utilize the NO
values measured at £ows 0?005 and 0?1l secÿ1 and
apply eqns (1) and (5) for both of them, resulting:
FENO0005  FwNOÿ I
DwNO
eÿ
DwNO
5 A3
FENO01  FwNOÿ I
DwNO
eÿ
DwNO
100 : A4
By subtracting these equations and rearranging we
get
FENO0005 ÿ FENO01
I
DwNO  eÿ
DwNO
100
ÿ eÿDwNO5 : A5
The left side is a line and the right one an exponential.
The solution for DwNO is their intercept inml sec
ÿ1and
then FwNO can be solved using eqn (5).
FWNO  I
DwNO FANO : A6
The bene¢t of this approach is a possibility to check if
the measured set of data points is consistent with the
model.This is based on the condition, that the eqn (A5)
has a solution only if the slope of the line is smaller than
that of the exponential at DwNO=0.We then ¢nd that a
solution to exist if:
FENO0005 ÿ FENO01
FENO01 ÿ FENO05 o23  75: A7
If this is not the case, the tested data set may su¡er
from errors inmeasuring the £oworNO concentration.
An additional test requires the sign of FANO to be posi-
tive. After these tests are passed, an iteration algorithm
is used to solve DwNO.The starting point for iteration is
FwNO4FENO0?005. Then by combining eqns (A1), (A2)and (A6) we get:
DwNO0  125FENO01 ÿ FENO05
FENO0005  0  25FENO01 ÿ 1  25FENO05 :
A8
For iterationwe developed the following sequence:
DwNOn1  1  25  e
ÿDn100 ÿ e
ÿDn
500  FENO01 ÿ FENO05
FENO01 ÿ FENO05 :
A9
This converges to the ¢nal value in less than10 rounds
and can be run in any spreadsheet by copying the eqn
(A9) into as many adjacent columns as needed. After
DwNOhas been found, FwNO is achieved from eqn (A6).
The accuracy can still be improved if the exponential
function in eqn (2) is approximated by
1ÿDwNO= _Q DwNO= _Q2=2. The second round of
iteration can then be run with new corrected starting
values of:
S0  Sÿ 105 D  I A10
I0  I  1 5  103 D: A11
Validation of the iteration algorithm
We tested the ability of the iteration algorithm to ¢nd
the three unknown parameters by constructing a num-
ber of randomly generated data sets of FwNO, FANO
and DwNO. For each set the values of FENO0?005,
FENO0?1and FENO0?5were calculatedusing eqn (1).These
were then given as an input to the iteration algorithm to
see how accurately it was able to reconstruct the origi-
nal set of FwNO, FANO and DwNO.
We constructed100 data sets using a random number
generator allowing the variation ranges for the para-
meters to independently be; FwNO: 30^300ppb, FANO:
1^6ppb andDwNO: 2^20ml sec
ÿ1.Thesewere judged to
adequately cover the ranges we have found in our volun-
teer and patientmeasurements.
The iterationwas successful for all the100 data sets.The
errors of the recovered values as compared to the origi-
nal oneswere; FwNO: 0?270?7%, FANO: 0?770?7% and
DwNO: ÿ1?871?1%.The result of the test indicates that
the iteration algorithm is robust and accurate enough for
practical use.
